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ECONOMIC EVALUATION OF A SAFETY DEVICE 
FOR SUBCUTANEOUS INJECTIONS OF LOW 
MOLECULAR WEIGHT HEPARIN (LMWH)
Durand-Zaleski I1, Gabriel S2, Dinet J2
1Hôpital Henri-Mondor, Creteil, France; 2Health Economics 
Department, Sanofi-Synthelabo, Bagneux, France
Subcutaneous injections account for an increasing share
of total needle-stick injuries (NSI). OBJECTIVE: The ob-
jective was to document the possible cost savings related
to the introduction of a protected needle (safety shaft)
used to administer LMWH. METHODS: We estimated
the frequency and the costs of NSI attributable to treat-
ment with LMWH in a tertiary care hospital, and mod-
eled a countrywide estimate. Risks: We collected data on
yearly NSI due to recapping in a large tertiary care center
and related this figure to the total number of needles
used. We derived a risk of NSI per 100,000 needles used
and multiplied it by the number of injections with
LMWH per year in hospitals countrywide. Costs: we esti-
mated the cost of a NSI from the resources used in the
hospital to manage personnel after a NSI. The actual re-
sources used were prospectively collected during the year
1997 and were compared to other observed data (hospi-
tal survey). From these data we built a decision tree and
compared the results to the recommended practice. Costs
were estimated from the viewpoints of both hospital and
society. Infection: the costs related to the risk of viral in-
fection were not included. RESULTS: The rate of NSI
due to recapping was 5.2 per 100,000 punctures, the to-
tal number of LMWH needles used in hospitals was
14,861,000. The total societal cost of managing a NSI
was assessed to be $1919 assuming that all the recom-
mended procedures were followed. From the hospital
viewpoint, the cost became $1174. The large discrepancy
between recommended and actual practice lead to signifi-
cant reductions in costs. The potential savings linked to
the use of the safety device were conservatively estimated.
CONCLUSION: Using safer devices for LMWH injec-
tions may result in cost savings by reducing the costs of
NSI management.
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MANAGING PNEUMOCYSTOSIS: THE COST OF 
HOSPITALIZATION IN THE US
O’Brien J, Pierce D, Caro J
Caro Research, Concord, MA, USA
Highly active antiretroviral therapy (HAART) has made
it possible to retard progression from the HIV positive
state to AIDS. Today’s health care decision-makers re-
quire the examination of the economic, as well as the
clinical consequences of emerging therapies. To under-
stand the full economic impact of HAART, it is necessary
to examine the cost consequences of transitioning from
HIV to AIDS. The occurrence of opportunistic infections
hallmarks this transition. OBJECTIVES: To determine
the hospitalization costs of pneumocystosis (pneumonia
due to Pneumocystis carinii), one of the more prevalent
opportunistic infections associated with AIDS. METH-
ODS: Cost estimates for inpatient care were developed
using data from 5 all payer, state 1996/97 discharge da-
tabases (CA, FL, MA, MD, WA). A strict hierarchical
methodology using ICD9 codes was used to identify
AIDS cases admitted primarily for treatment of pneu-
mocystosis. Disposition status was used to identify those
who died during hospitalization and post-discharge care.
Hospital costs include all accommodation and ancillary
services. Physician costs are not included. Costs are re-
ported in 1999 US $, adjusted appropriately for medical
inflation and cost-to-charge ratios. RESULTS: Of the
48,782 AIDS-related discharges identified, 1633 (3.3%)
were documented to be admitted primarily due to pneu-
mocystosis. During hospitalization, 9% of this group
died. The mean cost of hospitalization for those who died
($31,370) was three times greater than the average cost
for those who survived ($10,420). CONCLUSIONS:
Pneumocystosis represents a costly manifestation of
AIDS and highlights the cost consequences of AIDS man-
agement. Thus, understanding the difference in manage-
ment costs of HIV and AIDS is an integral component of
an economic analysis of new HAART regimens.
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The traditional treatment of Uncomplicated Acute Pyelo-
nephritis (UAP) is hospitalization and parenteral antibio-
therapy. Some authors suggest that administration of
oral antibiotics is as efficient as a traditional treatment
and allows ambulatory therapy. OBJECTIVES: The
study purpose was to compare, with identical demon-
strated effectiveness, the resources mobilized according
to two ways of managing women with UAP: inpatient
versus outpatient therapy. METHODS: We achieved a
multicentric (16 French emergency wards) and random-
ized cost-minimization analysis. Direct (fixed and vari-
able costs) and indirect (home help, transport charges,
stoppage) costs were calculated prospectively on 252 in-
patients and 250 outpatients. Several scenarii about the
avoided hospitalizations rate were studied (prefered sce-
nario: reduction of 50%, 15,000 annual hospitaliza-
tions). RESULTS: Ambulatory treatment reduces by
63% the direct medical costs (US$ 466 vs US$ 1278, P 
0.001) and of 2.3 days, the sick-leaves. The gain concerns
fixed costs, but also variable costs such as investigations.
The hypothesis of a transfer of expenditures to patients
was not demonstrated (US$ 29.6 vs US$ 26.5, P 
0.458). If the quality of care is similar (8.8/10 in each
